-+ 0.00%
-+ 0.00%
-+ 0.00%

Zymeworks says Phase 1 ZW191 posts 61% response rate in ovarian cancer cohort

PUBT·04/21/2026 21:30:27
Listen to the news
Zymeworks says Phase 1 ZW191 posts 61% response rate in ovarian cancer cohort
  • Zymeworks presented new Phase 1 results for folate receptor alpha-targeting ADC ZW191 at AACR Annual Meeting 2026.
  • Data showed encouraging tumor responses in heavily pretreated ovarian cancer and endometrial cancer, including activity across varying levels of target expression.
  • Safety profile appeared manageable, supporting continued clinical development.
  • Dose-optimization enrollment in ovarian cancer has completed, with results set to guide dose selection for potential registration studies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zymeworks Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604211730OMX_____CNEWS_EN_GNW9693991_en) on April 21, 2026, and is solely responsible for the information contained therein.